https://www.selleckchem.com/pr....oducts/ly3537982.htm
007). There was no significant difference in DFS and OS between ddNCT and standard NCT (DFS HR = 0.90, 95% CI 0.79‒1.02, P = 0.095; OS; HR = 0.91, 95% CI 0.81‒1.04, P = 0.16, regardless of hormone receptor expression levels. These data suggested the higher pCR rate in patients receiving ddNCT did not result in a survival benefit. Conclusions The meta-analysis demonstrated that ddNCT can significantly improve the pCR rate in patients with low hormone receptor expression levels, although patient survival was not significantly improved